Work

669P CBX-12-101: Final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors

Year: 2024

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.735

Authors: P. Lorusso, F. Meric-Bernstam, N. Hafez, I.I. Rodriguez Rivera, D. Tripathy, S. Wilks, P. Pearson, M.N. Needle, A.W. Tolcher

Institutions: Yale University, The University of Texas MD Anderson Cancer Center, Yale Cancer Center

Language: English

Topic: Nanoparticle-Based Drug Delivery

Subfield: Biomaterials

Field: Materials Science

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Regeneron Pharmaceuticals, G1 Therapeutics, Glenmark Pharmaceuticals, Genentech

OpenAlex ID: W4402560064

FWCI: 0.419

Cites:

Cited by: 5

Related to: 10